XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurement (Tables)
9 Months Ended
Sep. 30, 2023
Summary of Financial Items Carried at Fair Value
Financial items carried at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 are classified in the tables below in one of the three categories of fair value levels:
 
 
  
September 30, 2023
 
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
  
(U.S. $ in millions)
 
Cash and cash equivalents:
  
  
  
  
Money markets
   $ 824      $ —       $ —       $ 824  
Cash, deposits and other
     1,425        —         —         1,425  
Investment in securities:
                                   
Investment in convertible bond
     —         —         25        25  
Equity securities
     7        —         —         7  
Other
     5        —         —         5  
Restricted cash
     1        —         —         1  
Derivatives:
                                   
Asset derivatives:
                                   
Options and forward contracts
     —         44        —         44  
Cross currency interest rate swaps
     —         14        —         14  
Conversion option
     —         —         15        15  
Liability derivatives:
                                   
Options and forward contracts
     —         (40      —         (40
Bifurcated embedded derivatives
     —         —         §        —   
Contingent consideration*
     —         —         (68      (68
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
$
2,262
 
  
$
18
 
  
$
(28
  
$
2,252
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 

 
  
December 31, 2022
 
 
  
Level 1
 
    
Level 2
 
  
Level 3
 
  
Total
 
 
  
 
 
    
 
 
  
 
 
  
 
 
 
  
(U.S. $ in millions)
 
Cash and cash equivalents:
  
    
  
  
Money markets
   $ 1,222      $ —       $ —       $ 1,222  
Cash, deposits and other
     1,579        —         —         1,579  
Investment in securities:
                                   
Equity securities
     9        —         —         9  
Other
     5        —         1        6  
Restricted cash
     33        —         —         33  
Derivatives:
                                   
Asset derivatives—options and forward contracts
     —         29        —         29  
Liability derivatives:
                                   
Options and forward contracts
     —         (101      —         (101
Bifurcated embedded derivatives
     —         —         §        —   
Contingent consideration*
  
$
— 
 
  
 
— 
 
  
 
(153
  
 
(153
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
     2,848      $ (73    $ (152    $ 2,624  
    
 
 
    
 
 
    
 
 
    
 
 
 

§
Represents an amount less than $
0.5
 million. 
*
Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.
Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs
The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated ut
ilizi
ng Level 3 inputs:
 
 
  
Nine months ended

September 30, 2023
 
  
Nine months ended

September 30, 2022
 
 
  
 
 
  
 
 
 
  
(U.S. $ in millions)
 
Fair value at the beginning of the period
   $ (152      (175
Investment in convertible bond**
     25        —   
Conversion option**
     15        —   
Bifurcated embedded derivatives
     §        §  
Adjustments to provisions for contingent consideration:
                 
Actavis Generics transaction
     (77      (98
Eagle transaction
     (35      (2
Novetide transaction
     2        —   
Settlement of contingent consideration:
                 
Actavis Generics transaction
     132        106  
Eagle transaction
     61        68  
Novetide transaction
     2        —   
Additional contingent consideration resulting from Novetide acquisition*
     —         (11
    
 
 
    
 
 
 
Fair value at the end of the period
   $ (28    $ (112
    
 
 
    
 
 
 
 
§
Represents an amount less than $
0.5
 million.
*
In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated companies.” This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under “Share in (profits) losses of associated companies, net,” reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition.
**
On September 29, 2023, Teva invested $40 million in subordinated convertible bonds, which were issued by Alvotech, pursuant to a convertible bond instrument dated December 20, 2022.
(
s
ee note 2
)
.
Summary of Financial Instrument Measured on a Basis Other Than Fair Value
Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs):
 
 
  
Estimated fair value*
 
 
  
September 30,
 
  
December 31,
 
 
  
2023
 
  
2022
 
 
  
 
 
  
 
 
 
  
(U.S. $ in millions)
 
Senior notes and sustainability-linked senior notes included under senior notes and loans
   $ 16,629      $ 16,694  
Senior notes and convertible senior debentures included under short-term debt
     975        2,075  
    
 
 
    
 
 
 
Total
   $ 17,604      $ 18,769  
    
 
 
    
 
 
 

*
The fair value was estimated based on quoted market prices.